The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma

Epidermal growth factor receptor (EGFR) T790M mutation has shown to be associated with the clinical outcomes of patients after initial EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy in EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, its predictive role in EGFR-TKI re-challenge r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qiuyi, Ke, Ee, Niu, Feiyu, Deng, Wei, Chen, Zhihong, Xu, Chongrui, Zhang, Xuchao, Zhao, Ning, Su, Jian, Yang, Jinji, Yan, Honghong, Wu, Yilong, Zhou, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354886/
https://www.ncbi.nlm.nih.gov/pubmed/27999211
http://dx.doi.org/10.18632/oncotarget.14007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354886/
https://www.ncbi.nlm.nih.gov/pubmed/27999211
http://dx.doi.org/10.18632/oncotarget.14007

Ejemplares similares